NYSE$BSX

Boston Scientific Corp · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Boston Scientific's first quarter results for 2023 were announced, showcasing strong growth across all businesses and regions.

Boston Scientific reported net sales of $3.389 billion for the first quarter of 2023, representing a 12.0% increase on a reported basis. GAAP net income attributable to Boston Scientific common stockholders was $300 million, or $0.21 per share, while adjusted EPS reached $0.47.

  • Net sales increased by 12.0% on a reported basis, 14.9% on an operational basis, and 14.0% on an organic basis compared to the prior year period.
  • GAAP net income attributable to Boston Scientific common stockholders was reported at $0.21 per share, while adjusted EPS was $0.47 per share.
  • MedSurg segment net sales grew by 11.0% reported, 13.4% operational and organic.
  • Cardiovascular segment net sales increased by 12.7% reported, 15.9% operational and 14.4% organic.

Headline financials

Total Revenue

$3.39B

Previous: $3.03B+12.0%
EPS (adj)

$0.47

Previous: $0.39+20.5%
MedSurg organic growth

13.4%

Previous: 8.0%+67.5%
Cardio organic growth

14.4%

Previous: 10.8%+33.3%
Capital Expenditures

-$111M

Previous: -$121M+8.3%
Free Cash Flow

$203M

Previous: -$11M+1945.5%
Net Income

$314M

Previous: $110M+185.5%
Operating Income

$552M

Previous: $466M+18.5%
Gross Profit

$2.35B

Previous: $2.07B+13.4%
Cash & Equivalents

$570M

Previous: $325M+75.4%
Total Assets

$32.9B

Previous: $32.3B+1.7%
Stock-Based Comp

$55M

Previous: $52M+5.8%

Revenue & EPS history

Boston Scientific · Revenue · Quarterly

$3.39B

Q1 2023+12%vs Q1 2022
Beat estimate in 5 of 15 quarters(33%)
ActualEstimate

Revenue by segment

Boston Scientific · $3.39B total across 2 segments · Q1 2023

  • Cardiovascular
    $2.11B+12.7%
  • MedSurg
    $1.28B+11.0%

Forward guidance

The company estimates net sales growth for the full year 2023 to be approximately 8.5 to 10.5 percent on a reported basis, and approximately 8 to 10 percent on an organic basis. The company estimates EPS on a GAAP basis in a range of $0.93 to $1.02 and estimates adjusted EPS of $1.90 to $1.96.

Tailwinds

  • Net sales growth for the full year 2023 is estimated to be approximately 8.5 to 10.5 percent on a reported basis.
  • Organic net sales growth for the full year 2023 is projected to be approximately 8 to 10 percent.
  • EPS on a GAAP basis is estimated to be in the range of $0.93 to $1.02 for the full year 2023.
  • Adjusted EPS is projected to be between $1.90 and $1.96 for the full year 2023.
  • Net sales growth for the second quarter of 2023 is expected to be in the range of approximately 6.5 to 8.5 percent on a reported basis.

Headwinds

  • Foreign currency fluctuations are expected to impact net sales growth.
  • Acquisitions and divestitures may impact organic net sales growth.
  • GAAP EPS for the second quarter of 2023 is estimated to be in a range of $0.23 to $0.27.
  • Adjusted EPS for the second quarter of 2023 is projected to be between $0.48 and $0.50.
  • The company's estimates are subject to various risks and uncertainties, including economic, political, and regulatory conditions.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+0.9%

Avg return

Earnings day

+0.6%

Avg return

5 days after

+0.8%

Avg return

30 days after

64%

47 / 73 earnings

Positive

+14.0%

Q2 2013

Best reaction

-17.4%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+9.0%+0.7%-3.0%
Q4 2025-17.4%-19.1%-22.1%
Q3 2025+4.0%+2.5%-3.0%
Q2 2025+0.5%-1.9%+0.6%
Q1 2025+4.0%+7.5%+9.9%
Q4 2024+1.4%+2.5%-4.3%
Q3 2024-3.3%-3.7%+2.3%
Q2 2024-5.5%-3.8%+0.7%
Q1 2024+6.2%+5.1%+9.6%
Q4 2023+5.5%+4.9%+9.3%
Q3 2023-0.9%+2.4%+11.3%
Q2 2023-1.4%-1.0%-3.1%
Q1 2023+1.8%+3.3%-0.1%
Q4 2022+3.9%+3.0%+3.4%
Q3 2022+0.7%+4.4%+6.9%
Q2 2022+8.4%+8.1%+6.7%
Q1 2022+0.3%-2.3%-3.3%
Q4 2021-2.0%-1.4%+1.1%
Q3 2021-2.4%-3.4%-13.0%
Q2 2021+3.3%+3.7%+1.6%
Q1 2021+4.0%+2.9%+0.3%
Q4 2020+5.8%+8.0%+7.9%
Q3 2020-7.1%-4.2%-6.8%
Q2 2020+1.8%-0.7%+7.2%
Q1 2020+4.3%-0.3%+5.7%
Q4 2019+0.3%-1.5%-12.3%
Q3 2019+6.2%+8.9%+9.6%
Q2 2019-2.0%-1.4%-4.0%
Q1 2019+2.9%+2.3%+7.2%
Q4 2018+2.9%+4.1%+4.7%
Q3 2018+1.0%-1.8%-3.4%
Q2 2018+2.3%-1.9%+3.4%
Q1 2018+3.3%+0.8%+6.4%
Q4 2017-2.0%-4.4%-4.3%
Q3 2017-3.7%-5.0%-3.2%
Q2 2017-1.5%-3.4%-2.6%
Q1 2017+1.6%+2.4%+5.2%
Q4 2016+5.3%+5.3%+4.3%
Q3 2016-4.2%-2.0%-5.7%
Q2 2016+2.6%+2.2%+1.3%
Q1 2016+10.9%
Q4 2015-6.3%
Q3 2015+8.1%
Q2 2015-3.7%
Q1 2015-2.2%
Q4 2014+3.3%
Q3 2014+5.7%
Q2 2014+0.7%
Q1 2014-7.1%
Q4 2013-1.9%
Q3 2013-5.5%
Q2 2013+14.0%
Q1 2013+1.2%
Q4 2012+6.6%
Q3 2012-7.1%
Q2 2012-2.1%
Q1 2012+2.0%
Q4 2011+0.2%
Q3 2011-0.5%
Q2 2011-6.1%
Q1 2011-1.5%
Q4 2010+6.2%
Q3 2010+4.6%
Q2 2010+0.9%
Q1 2009-5.6%
Q1 2010-0.3%
Q4 2007+0.5%
Q4 2009+0.5%
Q3 2009+3.2%
Q3 2008+3.2%
Q4 2008+1.3%
Q2 2009+1.3%
Q2 2008+1.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro